Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | TGX221 | 1 | 72 | 3.2 | 5857.5 | 5723.8 | 1443.3 | 0.505 | 1.020 | 1.020 | 1.988 | BT20 TGX221 0 1 |
BT-20 | XL147 | 1 | 72 | 3.2 | 5132.5 | 6311.0 | 1443.3 | 0.505 | 0.815 | 0.813 | 2.128 | BT20 XL147 0 1 |
BT-20 | KIN001-244 | 1 | 72 | 3.2 | 5716.5 | 6295.0 | 1443.3 | 0.505 | 0.911 | 0.908 | 2.125 | BT20 KIN001-244 0 1 |
BT-20 | Sirolimus | 1 | 72 | 3.2 | 3597.5 | 5856.5 | 1443.3 | 0.505 | 0.571 | 0.614 | 2.021 | BT20 Rapamycin 0 1 |
BT-20 | Torin2 | 1 | 72 | 3.2 | 96.0 | 5846.0 | 1443.3 | 0.505 | -0.739 | 0.016 | 2.018 | BT20 Torin2 0 1 |
BT-20 | WYE-125132 | 1 | 72 | 3.2 | 2287.3 | 5739.3 | 1443.3 | 0.505 | 0.260 | 0.399 | 1.991 | BT20 WYE125132 0 1 |
BT-20 | Buparlisib | 1 | 72 | 3.2 | 495.8 | 6321.8 | 1443.3 | 0.505 | -0.394 | 0.078 | 2.131 | BT20 BKM120 0 1 |
BT-20 | Pictilisib | 1 | 72 | 3.2 | 1978.8 | 6125.0 | 1443.3 | 0.505 | 0.163 | 0.323 | 2.085 | BT20 GDC0941 0 1 |
BT-20 | Everolimus | 1 | 72 | 3.2 | 3453.3 | 5781.0 | 1443.3 | 0.505 | 0.546 | 0.597 | 2.002 | BT20 Everolimus 0 1 |
BT-20 | PIK-93 | 1 | 72 | 3.2 | 2878.0 | 5875.8 | 1443.3 | 0.505 | 0.406 | 0.490 | 2.025 | BT20 PIK93 0 1 |
BT-20 | Torin1 | 1 | 72 | 3.2 | 1153.3 | 5863.3 | 1443.3 | 0.505 | -0.105 | 0.197 | 2.022 | BT20 Torin1 0 1 |
BT-20 | BX-912 | 1 | 72 | 3.2 | 4618.5 | 6155.0 | 1443.3 | 0.505 | 0.743 | 0.750 | 2.092 | BT20 BX912 0 1 |
BT-20 | GDC-0980 | 1 | 72 | 3.2 | 730.3 | 5778.5 | 1443.3 | 0.505 | -0.289 | 0.126 | 2.001 | BT20 GDC0980 0 1 |
BT-20 | Trametinib | 1 | 72 | 3.2 | 3445.8 | 5837.3 | 1443.3 | 0.505 | 0.540 | 0.590 | 2.016 | BT20 Trametinib 0 1 |
BT-20 | AZD-6482 | 1 | 72 | 3.2 | 2032.7 | 5948.8 | 1443.3 | 0.505 | 0.182 | 0.342 | 2.043 | BT20 AZD6482 0 1 |
BT-20 | AS605240 | 1 | 72 | 3.2 | 5187.0 | 6371.0 | 1443.3 | 0.505 | 0.817 | 0.814 | 2.142 | BT20 AS605240 0 1 |
BT-20 | Dactolisib | 1 | 72 | 3.2 | 900.5 | 5998.3 | 1443.3 | 0.505 | -0.205 | 0.150 | 2.055 | BT20 BEZ235 0 1 |
BT-20 | Omipalisib | 1 | 72 | 3.2 | 95.5 | 6095.3 | 1443.3 | 0.505 | -0.729 | 0.016 | 2.078 | BT20 GSK458 0 1 |
BT-20 | CAL-101 | 1 | 72 | 3.2 | 5408.0 | 6240.0 | 1443.3 | 0.505 | 0.869 | 0.867 | 2.112 | BT20 CAL101 0 1 |
BT-20 | Alpelisib | 1 | 72 | 3.2 | 1584.5 | 6091.5 | 1443.3 | 0.505 | 0.046 | 0.260 | 2.077 | BT20 BYL719 0 1 |
BT-20 | MK2206 | 1 | 72 | 3.2 | 5077.7 | 6138.5 | 1443.3 | 0.505 | 0.826 | 0.827 | 2.089 | BT20 MK2206 0 1 |
BT-20 | PI103 | 1 | 72 | 3.2 | 1411.8 | 5476.0 | 1443.3 | 0.505 | -0.011 | 0.258 | 1.924 | BT20 PI103 0 1 |
BT-20 | AZD8055 | 1 | 72 | 3.2 | 2067.3 | 5941.5 | 1443.3 | 0.505 | 0.192 | 0.348 | 2.041 | BT20 AZD8055 0 1 |
BT-20 | AS605240 | 2 | 72 | 3.2 | 2797.5 | 3661.0 | 1018.6 | 0.505 | 0.729 | 0.764 | 1.846 | BT20 AS605240 0 2 |
BT-20 | ZSTK474 | 1 | 72 | 3.2 | 1504.8 | 5537.8 | 1443.3 | 0.505 | 0.022 | 0.272 | 1.940 | BT20 ZSTK474 0 1 |